MX2016008441A - Formulacion de factor de crecimiento de fibroblastos 18 en geles de xiloglucano. - Google Patents

Formulacion de factor de crecimiento de fibroblastos 18 en geles de xiloglucano.

Info

Publication number
MX2016008441A
MX2016008441A MX2016008441A MX2016008441A MX2016008441A MX 2016008441 A MX2016008441 A MX 2016008441A MX 2016008441 A MX2016008441 A MX 2016008441A MX 2016008441 A MX2016008441 A MX 2016008441A MX 2016008441 A MX2016008441 A MX 2016008441A
Authority
MX
Mexico
Prior art keywords
fgf
formulation
hydrogels
xyloglucan
gels
Prior art date
Application number
MX2016008441A
Other languages
English (en)
Inventor
Lo Presti Caterina
Bulone Donatella
DISPENZA Clelia
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of MX2016008441A publication Critical patent/MX2016008441A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus

Abstract

La invención se refiere al campo de las formulaciones farmacéuticas; más en particular, está dirigida a hidrogeles de xiloglucano que comprenden un compuesto de factor de crecimiento de fibroblastos 18 (FGF-18) y a métodos para producción de dicho hidrogeles; los hidrogeles de la invención se pueden usar, una vez formados in situ, para el tratamiento de trastornos de cartílago tales como osteoartritis o lesión de cartílago.
MX2016008441A 2013-12-24 2014-12-23 Formulacion de factor de crecimiento de fibroblastos 18 en geles de xiloglucano. MX2016008441A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199588 2013-12-24
PCT/EP2014/079194 WO2015097233A1 (en) 2013-12-24 2014-12-23 Fgf-18 formulation in xyloglucan gels

Publications (1)

Publication Number Publication Date
MX2016008441A true MX2016008441A (es) 2017-01-11

Family

ID=49882941

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008441A MX2016008441A (es) 2013-12-24 2014-12-23 Formulacion de factor de crecimiento de fibroblastos 18 en geles de xiloglucano.

Country Status (16)

Country Link
US (1) US10293051B2 (es)
EP (1) EP3086803B1 (es)
JP (1) JP6791754B2 (es)
KR (2) KR102622290B1 (es)
CN (1) CN106029085B (es)
AU (1) AU2014372575B2 (es)
BR (1) BR112016014578B1 (es)
CA (1) CA2934470C (es)
ES (1) ES2865723T3 (es)
IL (1) IL246435B (es)
MX (1) MX2016008441A (es)
NZ (1) NZ721332A (es)
RU (1) RU2695343C2 (es)
SG (1) SG11201604927RA (es)
WO (1) WO2015097233A1 (es)
ZA (1) ZA201604609B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6487448B2 (ja) 2013-12-24 2019-03-20 アレス トレーディング ソシエテ アノニム アルギネート／コラーゲンヒドロゲル中のｆｇｆ−１８製剤
WO2024084807A1 (ja) * 2022-10-19 2024-04-25 学校法人東邦大学 線維芽細胞増殖因子１８の測定方法及び測定用試薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029777A1 (fr) * 1996-02-13 1997-08-21 Dainippon Pharmaceutical Co., Ltd. Systeme d'administration de medicament utilisant une galactoxyloglucane
CA2689694A1 (en) * 1999-07-21 2001-02-01 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
AU2003279835B2 (en) * 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
US7217294B2 (en) * 2003-08-20 2007-05-15 Histogenics Corp. Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and method for use thereof
CA2658511C (en) * 2006-08-25 2019-02-19 Ares Trading S.A. Use of fgf-18 compound to treat cartilage disorders
CN102600066A (zh) * 2012-04-01 2012-07-25 山东喜丰田生态肥业有限公司 一种含有扑热息痛的温度敏感凝胶缓释口服剂
WO2014062538A1 (en) * 2012-10-19 2014-04-24 3M Innovative Properties Company Polysaccharide-containing hydrogels, compositions, articles, and methods
JP6487448B2 (ja) 2013-12-24 2019-03-20 アレス トレーディング ソシエテ アノニム アルギネート／コラーゲンヒドロゲル中のｆｇｆ−１８製剤

Also Published As

Publication number Publication date
CN106029085A (zh) 2016-10-12
BR112016014578B1 (pt) 2023-01-24
AU2014372575B2 (en) 2020-07-09
KR102622290B1 (ko) 2024-01-05
RU2016129827A3 (es) 2018-09-03
KR20220054446A (ko) 2022-05-02
SG11201604927RA (en) 2016-07-28
CA2934470A1 (en) 2015-07-02
AU2014372575A1 (en) 2016-07-07
ZA201604609B (en) 2022-05-25
BR112016014578A2 (pt) 2017-10-24
NZ721332A (en) 2022-07-01
US10293051B2 (en) 2019-05-21
RU2695343C2 (ru) 2019-07-23
EP3086803B1 (en) 2021-02-17
ES2865723T3 (es) 2021-10-15
JP6791754B2 (ja) 2020-11-25
CA2934470C (en) 2023-06-27
US20160317668A1 (en) 2016-11-03
JP2017502043A (ja) 2017-01-19
IL246435B (en) 2021-03-25
EP3086803A1 (en) 2016-11-02
IL246435A0 (en) 2016-08-31
KR20160102032A (ko) 2016-08-26
CN106029085B (zh) 2020-08-04
RU2016129827A (ru) 2018-01-30
WO2015097233A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
MX368970B (es) Formulacion de factor de crecimiento de fibroblastos 18 en hidrogeles de alginato/colageno.
PH12019501533A1 (en) Tigit-and light-based chimeric proteins
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
EP3318564A3 (en) Bicyclic heterocycles as fgfr inhibitors
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX2018011249A (es) Composiciones topicas no acuosas que comprenden una salicilanilida halogenada.
WO2015085318A3 (en) Targeted adaptive vaccines
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
UA115983C2 (uk) Інгібітори днк-пк
BR112015024846A2 (pt) composições para utilização no estímulo do crescimento ósseo
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
EP3760638A3 (en) Compositions and methods utilizing lysophosphatidylcholine scaffolds
MX2016013447A (es) Heterociclilsulfonas heteroarilo sustituidas.
PH12017501070A1 (en) Peptides and their use in the treatment of skin
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MY170630A (en) Freeze-dried formulations of fgf-18
WO2013123249A3 (en) Formulations and methods for treating ear conditions
WO2016149659A3 (en) Antisense-induced exon exclusion in myostatin
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
MY191337A (en) Compositions for the treatment of hypertension and/or fibrosis
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.

Legal Events

Date Code Title Description
FG Grant or registration